In vitro antibody selection

YUMAB’s advanced in vitro antibody generation pipeline employs phage display selection in combination with our proprietary universal naive human antibody gene libraries (HAL) or customized immune libraries.

The principle of antibody phage display based on large libraries of bacteriophage particles, each carrying the genetic information and the unique phenotypic binding function of one antibody clones. In vitro selection is performed by the molecular interaction of target and antibody phage. Several selection rounds result in the enrichment of antigen-specific antibody phage. Monoclonal antibodies are finally identified by soluble expression and screening using different types of immunoassays.


Due to the resemblance with the gold washer’s method to extract gold, the in vitro selection process is termed „panning“. The panning is completely independent of animal immunizations and helps to reduce unnecessary animal experiments. Moreover, bypassing the in vivo immune response has many advantages, particularly for difficult targets like highly conserved, non-immunogenic, instable, or toxic proteins.

YUMAB can tightly control biochemical conditions to guide antibody selection to higher specificity and lower cross-reactivity, respectively. Specificity and cross-reactivity can be even targeted to certain epitopes, e.g. shared epitopes of the human and murine protein. We can also match your final assay conditions (e.g., buffer, salt, pH, allosteric conformation of the antigen, competitors, etc.) during in vitro selection to generate antibodies that will better work in your application.

Antibody gene sequences are immediately isolated, which dramatically facilitates following steps like conversion in other recombinant antibody formats (IgG, Yumab/scFv-Fc, Fab, scFv, bispecific and antibody fusion proteins) or antibody engineering (optimization for affinity, stability, manufacturability) to improve antibodies for your application and to reduce the time to product.


YUMAB’s antibody phage display technology has been proven robust and successful to more than 300 antigens, mostly of human origin, and has already resulted in several human antibody leads.

Key features of YUMAB’s antibody phage display technology:

  • Very fast (from selection to delivery of purified Yumabs  in less than 6 weeks)
  • Large scale (parallelized and automated selection)
  • No animal immunizations = less animal experiments
  • Very low antigen consumption (100-200 µg protein for standard selection)
  • Difficult antigens including highly conserved and toxic antigens

Tailored selection conditions allow the pre-definition of biochemical and functional properties of antibodies during their making with endless novel opportunities including:

  • Pre-selection against cross reactivity to homologous proteins or serum components
  • Selection of antibodies with mouse-human cross reactivity
  • Phosphospecific antibodies for individual phosphorylations
  • Selection of compatible sandwich antibody pairs
  • Panning to identify common epitopes de novo